Why the Novo Nordisk and Hims & Hers Deal Is a Win for Both Stocks

To say that pharmaceutical giant Novo Nordisk (NYSE: NVO) has had a tumultuous relationship with telehealth company Hims & Hers Health (NYSE: HIMS) in the past year would be a bit of an understatement. The two companies have gone from working together to Novo Nordisk suing Hims & Hers. Most recently, however, they have announced a deal where Hims & Hers Health will be able to sell Novo Nordisk's popular GLP-1 drugs, Ozempic and Wegovy. Finally, it looks as though the drama involving the two companies may ...